Abstract
ADG106, a human anti-CD137 IgG4 agonist antibody engineered using Adagene’s NEObody™ technology, binds specifically and with high affinity to a unique and conserved epitope of CD137 on activated human T cells. ADG106 blocks CD137 ligand binding and stimulates CD4+ and CD8+ T cell proliferation and proinflammatory interferon-gamma (IFN-γ) release while displaying a low risk for adverse immune responses. We present here studies of changes in immune activation associated pharmacodynamic (PD) markers, including soluble CD137 (sCD137) following treatment with ADG106 alone or combined with toripalimab, an anti-PD-1 antibody.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call